Polar body array CGH for prediction of the status of the corresponding oocyte. Part I: clinical results

Joep Geraedts1, Markus Montag2, M. Cristina Magli3; Sjoerd Repping4, Alan Handyside5, Catherine Staessen6, Joyce Harper7,8, Andreas Schmutsler9, John Collins10, Veerly Goossens11, Hans van der Ven2, Katerina Vesela12, and Luca Gianaroli3. 
1. Department of Genetics and Cell Biology, Research Institute GROZ, Faculty of Health, Medicine and Life Science, Maastricht University, PO Box 58000, Maastricht, AZ 6202, The Netherlands
2. Department of Gynecological Endocrinology & Reproductive Medicine, University of Bonn, Bonn, Germany
3. Department of Reproductive Medicine, SISMER, Via Mazzini 12, Bologna 40138, Italy
4. Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5. London Bridge Fertility, Gynaecology and Genetics Centre, London and Faculty of Biological Sciences, University of Leeds, Leeds, UK
6. Centre for Medical Genetics, University Hospital, Brussels, Belgium
7. UCL Centre for PG&D, Institute for Women’s Health, University College London, London, UK
8. Centre for Reproductive and Genetic Health, UCLH, London, UK
9. Centre for Reproductive Medicine, University Women’s Hospital, Christian-Albrechts-University Kiel, Kiel, Germany
10. Department of Obstetrics & Gynecology, McMaster University, Hamilton, Canada
11. ESHRE Central Office, Grimbergen, Belgium
12. Sanatorium Repromeda, Brno, Czech Republic 


Background: Several randomized controlled trials have not shown a benefit from preimplantation genetic screening (PGS) biopsy of cleavage-stage embryos and assessment of up to 10 chromosomes for aneuploidy. Therefore, a proof-of-principle study was planned to determine the reliability of alternative form of PGS, i.e. PGS by polar body (PB) biopsy, with whole genome amplification and microarray-based comparative genomic hybridization (array CGH) analysis


Parc d'activités Activestre
31390 Carbonne - FRANCE


Phone +33 561 971 974
Fax +33 561 971 975